An observational study to evaluate the effectiveness and safety of Bilastine in patients with pruritus associated with skin disorders

SkinSpace Clinic0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Both males and females patients aged >= 18 years and <= 60 years
•2.Patients with H/O pruritus associated with skin disorders
•3.Patients who are ready to give written informed consent, which includes a commitment to comply with all requirements, specified in the study protocol
•4.Patients who the study staff deems reliable and mentally competent to carry out the study

•1.Patients with physical urticaria (e.g. solar, heat, cold, aquagenic, cholinergic, contact, pressure, etc.), drug-induced urticaria, urticarial vasculitis, senile pruritus or hereditary angioedema.
•2.Patients with pruritus due to metabolic diseases, neurologic disorders, endocrine diseases, psychiatric disorders, and cancer.
•3.Pregnant or nursing females.
•4.Patients with known hypersensitivity to the study drug.
•5.Patients with immunosuppressive disease or on immunosuppressive drugs.
•6.Evidence of clinically significant disease (e.g., cardiac, respiratory, gastrointestinal, renal disease) that in the opinion of the Investigator(s) could affect the subjectâ??s safety or interfere with the study assessments.
•7.Any history of or concomitant medical condition that in the opinion of the Investigator(s) would compromise the patientâ??s ability to safely complete the study.
•8.History of drug or alcohol dependency or abuse within approximately the last 2 years.
•9.Currently enrolled in another clinical study or used any investigational drug or device within 30 days preceding informed consent or were scheduled to participate in another clinical study that involved an investigational product or investigational drug during the course of this study.

发起方

SkinSpace Clinic